Sun Pharma launches only approved sprinkle formulation cap

Sun Pharma launched Ezallor Sprinkle (rosuvastatin) capsules in the US market to treat three kinds of elevated lipid disorders for people who have difficulty in swallowing. It is the first and only FDA-approved sprinkle formulation of rosuvastatin capsules.

The capsule is an adjunct to diet for treating adult patients having hypertriglyceridemia, primary dysbetalipoproteinemia (Type III hyperlipoproteinemia), lipid-lowering treatments, homozygous familial hypercholesterolemia, etc. In a press release, the company stated that this formulation product is a step towards increasing the company’s commitment to countering the medication administration challenges being faced with patients having difficulty in swallowing. Ezallor Sprinkle has been formulated as extended-release-coated pellets thus allowing it to be sprinkled over soft food. This makes it easy to be swallowed as a whole or to be administered via a nasogastric tube for facilitating long-term and once-daily administration. The medication is Sun Pharma’s second product specially designed for long-term care individuals following Kapspargo Sprinkle (metoprolol succinate) extended-release capsules.

The Ezallor Sprinkle has been made available in 5-mg, 10-mg, 20-mg, and 40-mg dose strengths. The product can be taken with or without food anytime during the day.

Sun Pharmaceutical Industries Limited is a specialty generic pharma giant manufacturing and selling pharmaceutical formulations and active pharmaceutical ingredients (APIs) mainly in India and the United States.

On Monday, the stock of the company was trading at Rs. 419.25 per share up by 2.83 per cent or Rs. 11.55 per share. The 52-week high is Rs. 678.80 and 52-week low is Rs. 350.40 on BSE.